+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Advances Against Aspergillosis I. Medical Science, Volume 1272. Edition No. 1. Annals of the New York Academy of Sciences

  • ID: 2335433
  • Book
  • February 2013
  • Region: United States
  • 252 Pages
  • John Wiley and Sons Ltd

Aspergillosis, the leading fungal cause of mortality in immunocompromised patients, presents a serious worldwide challenge - particularly in the face of increasing antifungal resistance.  Bringing together the world’s leaders in the Aspergillus and aspergillosis fields to promote cross-disciplinary collaboration among clinicians, industry, and scientific experts, the “Advances Against Aspergillosis” conference was held January 26–28, 2012 in Istanbul, Turkey. 

This first of two Annals volumes contains short reviews encapsulating recent clinical findings on aspergillosis.  Among the topics included are the application of diagnostic markers to invasive aspergillosis in children, risk stratification for invasive aspergillosis in immunocompromised patients, use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis,   immune regulation in idiopathic bronchiectasis, and management of chronic pulmonary aspergillosis.

NOTE: Annals volumes are available for sale as individual books or as a journal. Members of the New York Academy of Science receive full-text access to Annals online and discounts on print volumes.

Note: Product cover images may vary from those shown

Preface for Advances Against Aspergillosis Karl V. demons David S. Perlin Malcolm Richardson vii

Aspergillosis in the Clinic

Application of diagnostic markers to invasive aspergillosis in children Emmanuel Roilides Zoi-Dorothea Pana 1

Azole resistance in Aspergillus: global status in Europe and Asia Sevtap Arikan-Akdagli 9

The impact of azole resistance on aspergillosis guidelines Sarah P. Georgiadou Dimitrios P. Kontoyiannis 15

Risk stratification for invasive aspergillosis in immunocompromised patients Raoul Herbrecht Pierre Bories Jean-Charles Moulin Marie-Pierre Ledoux Valérie Letscher-Bru 23

Invasive aspergillosis in the intensive care unit George Dimopoulos Frantezeska Frantzeskaki Garyfallia Poulakou Apostolos Armaganidis 31

Management of chronic pulmonary aspergillosis Koichi Izumikawa Masato Tashiro Shigeru Kohno 40

The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis Richard B. Moss 49

Multifocal pulmonary aspergillomas: case series and review Matthew Pendleton David W. Denning 58

Immune regulation in idiopathic bronchiectasis Rosemary J. Boyton Daniel M. Altmann 68

Aspergillus bronchitis without significant immunocompromise Ales Chrdle Sahlawati Mustakim Rowland J. Bright-Thomas Caroline G. Baxter Timothy Felton David W. Denning 73

Note: Product cover images may vary from those shown
Karl V. Clemons Stanford University; Santa Clara Valley Medical Centre.

Malcolm D. Richardson University of Helsinki, Finland.

David S. Perlin
Note: Product cover images may vary from those shown
Adroll
adroll